19.08.2022 • News

Evonik to Expand Matting Agents in Taiwan

Evonik is expanding production capacity for its Acematt-branded matting agents at its site in Taiwan.

Without quantifying the size of the expansion, the company said the increase will be “significant” and will help to meet the rising demand for the coatings additives.

The new capacity is expected to be in the market during the second half of 2023. The German specialty chemicals producer said the matting agents manufactured in Taiwan exhibit the same properties as those made at its site in Bonn, Germany.

Evonik said the brand offers a variety of products to the coatings formulator, including finding the right balance of effectiveness for matting properties and easy integration into the coating system.

What’s more, the Essen-based chemical producer said Acematt products can enable formulators to reach the full spectrum of matting levels from semi-gloss to ultra-deep matt. Areas of application in industry and transportation range from textile to plastic, leather, can and coil coatings

“The capacity expansion of our leading matting agents in Taiwan further emphasizes our commitment to the growing markets in Asia and to all our regional and multi-national customers,” said Maximilian Morin, head of Industrial & Transportation Coatings at Evonik Coating Additives.

Morin said the company is continuously expanding its position as a global partner for the coatings industry by offering the same high quality products from manufacturing locations in multiple regions. Amid rising logistical challenges, such an investment will also directly help to improve the supply situation worldwide, he added.

Author: Dede Williams, Freelance Journalist

© Evonik
© Evonik

Company

Logo:

Evonik Technology & Infrastructure GmbH (Marl)

Paul-Baumann-Str. 1
45772 Marl
Germany

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read